AEGiS-14IAC: Effect of Nevirapine (NVP) for perinatal HIV prevention appears strong among women with advanced disease: Subgroup analyses of HIVNET 012.

14th International AIDS Conference

Barcelona, Spain - July 7-12, 2002

Effect of Nevirapine (NVP) for perinatal HIV prevention appears strong among women with advanced disease: Subgroup analyses of HIVNET 012.

Int Conf AIDS 2002 Jul 7-12; 14:(abstract no. TuOrB1174)

Nakabiito C, Guay LA, Musoke P, Fleming T, Jackson JB, Mmiro F, Fowler MG, Mwatha A
MU-JHU Research Collaboration, Kampala, Uganda

BACKGROUND: HIVNET 012 was a phase II randomized open label trial in Uganda which demonstrated an overall efficacy of 42% for the two dose NVP given to HIV infected mothers at labor onset and to their neonates, compared to intrapartum and 1 week post partum zidovudine (ZDV) for reducing perinatal HIV transmission. Subgroup analyses of 6 week and 18 month transmission rates by maternal CD4 count are described below.

METHODS: Subgroup analyses of CD4 were done using Kaplan Meier survival analyses. Transmission outcomes were based on infant RNA PCR.

RESULTS: Subgroup data for 583 women in the trial were analyzed. Lower transmission rates for women on NVP compared to ZDV were noted across all strata but differences were greatest among women with the lowest CD4. Transmission Rates (%) at 6 wk and 18 mo by CD4 Subgroups, KM

METHOD: CD4 Counts >=500 350-499 200-349 <=200 ZDV 6 wk 10.3% 23.0% 22.6% 35.4% NVP 8.9% 6.5% 18.2% 21.7% ZDV 18 mo 12.4% 24.7% 29.8% 54.9% NVP 11.2% 10.5% 22.6% 31.6%

CONCLUSIONS: These data support the efficacy of the simple NVP two dose peripartum regimen including women with the most advanced HIV disease.

Keywords: AEGIS, Nevirapine, Zidovudine, HIV Infections, CD4 Lymphocyte Count, HIV Seropositivity, Uganda, Human, Female, Infant, Pregnancy, prevention & control, transmission

020707
TuOrB1174